CN102639562A - 对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体 - Google Patents

对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体 Download PDF

Info

Publication number
CN102639562A
CN102639562A CN2010800256287A CN201080025628A CN102639562A CN 102639562 A CN102639562 A CN 102639562A CN 2010800256287 A CN2010800256287 A CN 2010800256287A CN 201080025628 A CN201080025628 A CN 201080025628A CN 102639562 A CN102639562 A CN 102639562A
Authority
CN
China
Prior art keywords
human monoclonal
monoclonal antibody
antibody
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800256287A
Other languages
English (en)
Chinese (zh)
Inventor
M.鲁道夫
H.科克
S.法斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenta Biotech AG
Original Assignee
Kenta Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech AG filed Critical Kenta Biotech AG
Publication of CN102639562A publication Critical patent/CN102639562A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800256287A 2009-04-09 2010-04-06 对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体 Pending CN102639562A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09005245.7 2009-04-09
EP09005245 2009-04-09
PCT/EP2010/002158 WO2010115606A1 (en) 2009-04-09 2010-04-06 Human monoclonal antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
CN102639562A true CN102639562A (zh) 2012-08-15

Family

ID=40934847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800256287A Pending CN102639562A (zh) 2009-04-09 2010-04-06 对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体

Country Status (10)

Country Link
US (1) US20120114657A1 (https=)
EP (1) EP2417157A1 (https=)
JP (1) JP2012523221A (https=)
KR (1) KR20120016086A (https=)
CN (1) CN102639562A (https=)
BR (1) BRPI1013427A2 (https=)
CA (1) CA2758081A1 (https=)
IL (1) IL215549A0 (https=)
MX (1) MX2011010634A (https=)
WO (1) WO2010115606A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120128686A (ko) * 2010-02-18 2012-11-27 심포젠 에이/에스 녹농균의 혈청형 ａ 지질다당류에 대한 항체
RU2014100111A (ru) * 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690875A1 (en) * 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690875A1 (en) * 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
（MICHAEL S. COLLINS ET AL.: "Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa", 《FEMS MICROBIOLOGY IMMUNOLOGY》 *
HANS J. ZWEERINK ET AL.: "Human Monoclonal Antibodies That Protect Mice against Challenge with Pseudomonas aeruginosa", 《INFECTION AND IMMUNITY》 *

Also Published As

Publication number Publication date
MX2011010634A (es) 2012-03-06
IL215549A0 (en) 2011-12-29
CA2758081A1 (en) 2010-10-14
BRPI1013427A2 (pt) 2016-04-05
WO2010115606A1 (en) 2010-10-14
KR20120016086A (ko) 2012-02-22
US20120114657A1 (en) 2012-05-10
JP2012523221A (ja) 2012-10-04
EP2417157A1 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
RU2687588C2 (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
JP5781765B2 (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
RU2529946C9 (ru) Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса
JP2011505381A5 (https=)
CN102639562A (zh) 对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
EP1479695B1 (en) Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
WO2014142117A1 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815